Literature DB >> 20377811

Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis.

Radhika N Bukkapatnam1, Nicole B Gabler, William R Lewis.   

Abstract

The benefits of statins on prevention of coronary heart disease in women without heart disease have not been clarified. The authors systematically reviewed all the published literature on primary prevention trials and found 6 primary prevention trials to date with sex-specific data on mortality and coronary heart disease events in women. The summary risk ratio for primary prevention of all-cause mortality was 0.90 (95% confidence interval, 0.60-1.35; P=.61) and for any coronary heart disease event was 0.78 (95% confidence interval, 0.64-0.96; P=.02). This review reveals that statin therapy along with diet and exercise in moderately hyperlipidemic women without a previous history of cardiovascular disease is of significant benefit in preventing coronary heart disease events but of no proven benefit in preventing all-cause mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20377811     DOI: 10.1111/j.1751-7141.2009.00059.x

Source DB:  PubMed          Journal:  Prev Cardiol        ISSN: 1520-037X


  14 in total

Review 1.  Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.

Authors:  Kunal N Karmali; Donald M Lloyd-Jones; Mark A Berendsen; David C Goff; Darshak M Sanghavi; Nina C Brown; Liliya Korenovska; Mark D Huffman
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

Review 2.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

Review 3.  Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths.

Authors:  Salim S Virani
Journal:  Tex Heart Inst J       Date:  2013

4.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 5.  Primary and secondary prevention of ischemic heart disease in women.

Authors:  Priya Kohli
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

Review 6.  Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2019-03       Impact factor: 3.275

7. 

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2019-03       Impact factor: 3.275

Review 8.  What the guidelines do not say: statin non-benefit groups.

Authors:  Pamela B Morris; Kellie McLain
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 9.  Women Versus Men: Is There Equal Benefit and Safety from Statins?

Authors:  Roda Plakogiannis; Sally A Arif
Journal:  Curr Atheroscler Rep       Date:  2016-02       Impact factor: 5.113

Review 10.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.